[HTML][HTML] DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes
L Shen, H Kantarjian, Y Guo, E Lin, J Shan… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2010•ncbi.nlm.nih.gov
Purpose The current classification systems of myelodysplastic syndromes (MDS), including
the International Prognostic Scoring System (IPSS), do not fully reflect the molecular
heterogeneity of the disease. Molecular characterization may predict clinical outcome and
help stratify patients for targeted therapies. Epigenetic therapy using decitabine, a DNA
hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we
investigated the association between DNA methylation and clinical outcome in MDS.
the International Prognostic Scoring System (IPSS), do not fully reflect the molecular
heterogeneity of the disease. Molecular characterization may predict clinical outcome and
help stratify patients for targeted therapies. Epigenetic therapy using decitabine, a DNA
hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we
investigated the association between DNA methylation and clinical outcome in MDS.
Abstract
Purpose
The current classification systems of myelodysplastic syndromes (MDS), including the International Prognostic Scoring System (IPSS), do not fully reflect the molecular heterogeneity of the disease. Molecular characterization may predict clinical outcome and help stratify patients for targeted therapies. Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we investigated the association between DNA methylation and clinical outcome in MDS.
ncbi.nlm.nih.gov